€420.10
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Vertex
sharewise wants to provide you with the best news and tools for Vertex, so we directly link to the best financial data sources.
Financials
News
Vertex Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
- Vertex reported strong Q2 growth: Revenue rose 12% year over year to $3.3 billion, prompting
Vertex Q2 Earnings Call Highlights
Key Points
- Interested in Vertex, Inc.? Here are five stocks we like better.
- Strong Q2 profitability: Revenue increased 10.5% year over year to $204 million, while adjusted EBITDA rose 33% to $51
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Key Points
- Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
- Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 per share in cash
Vertex’s Crinetics Deal Balances Growth with Integration Risk
Key Points
- Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
- Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
Key Points
- Interested in iShares Biotechnology ETF? Here are five stocks we like better.
- The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the
MaxCyte Q1 Earnings Call Highlights
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL
Vertex Q1 Earnings Call Highlights
Vertex (NASDAQ:VERX) reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
The
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
A banner Tuesday for U.S. stocks was also a prosperous one for Vertex Pharmaceuticals' (NASDAQ: VRTX) shares. The company reported encouraging, if not spectacular, quarterly results, and investors
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the cystic fibrosis (CF) drug market for more than a decade. This has been a very lucrative business for the biotech, and it could continue
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
When a company acquires another business, there's often going to be a premium involved, especially if it's in good shape or has some promising assets in its portfolio. But normally, you don't see a
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has a robust business that centers around cystic fibrosis therapies. But its growth rate has been slowing down of late. And despite having a stellar pipeline
Is This Biotech Stock a Buy Near Its 52-Week High?
The first five months of 2026 were rough on Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech's shares moved in the wrong direction through early June. However, the drugmaker has bounced back in
Why This Pharmaceutical Stock Jumped Close to 100% This Week
Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) jumped 98% this week, according to data from S&P Global Market Intelligence. The upstart drugmaker is being acquired by Vertex Pharmaceuticals for
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotech company that has steadily delivered growth to investors, thanks to its dominance in cystic fibrosis (CF) treatment. The company's portfolio of CF
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (NASDAQ:VRTX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) announced in a joint press release that Vertex is
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
Vertex Pharmaceuticals (NASDAQ: VRTX) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85 per share in cash. That works out
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
When a stock hits a 52-week high, that's a great sign the business is doing well. And when it hits a new all-time high, then you know the market is really excited about what's ahead for the
While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead
No stock has generated more buzz in recent weeks than Space Exploration Technologies (NASDAQ: SPCX), more commonly known as SpaceX. That's understandable, considering the space technology and
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing a high-growth newcomer against a cash-generating giant. Both companies aim to
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Choosing between a high-growth clinical-stage player and an established industry titan can be difficult for investors. This comparison examines Dyne Therapeutics (NASDAQ:DYN) and Vertex
Why Vertex Stock Is Rising Today
Starting the week on an auspicious note, Vertex (NASDAQ: VERX) stock is rising this morning. Shares of the software company are bouncing higher after an analyst initiated coverage with a bullish
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Deciding between CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing high-growth gene-editing potential against a profitable, established leader. Both